413 related articles for article (PubMed ID: 16950808)
21. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
Pollard RP; Abdulahad WH; Vissink A; Hamza N; Burgerhof JG; Meijer JM; Visser A; Huitema MG; Spijkervet FK; Kallenberg CG; Bootsma H; Kroese FG
Ann Rheum Dis; 2013 Jan; 72(1):146-8. PubMed ID: 22851468
[No Abstract] [Full Text] [Related]
23. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
[TBL] [Abstract][Full Text] [Related]
24. [Is rituximab a promising treatment for Sjögren's syndrome?].
Devauchelle-Pensec V; Pers JO; Youinou P; Saraux A
Rev Med Interne; 2008 Dec; 29(12):967-70. PubMed ID: 18403066
[No Abstract] [Full Text] [Related]
25. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
26. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
27. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
28. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in primary Sjögren's syndrome: one-year followup.
Steinfeld SD; Demols P; Appelboom T
Arthritis Rheum; 2002 Dec; 46(12):3301-3. PubMed ID: 12483735
[TBL] [Abstract][Full Text] [Related]
30. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
31. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
32. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
33. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
[TBL] [Abstract][Full Text] [Related]
34. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
[TBL] [Abstract][Full Text] [Related]
35. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
[TBL] [Abstract][Full Text] [Related]
36. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
[TBL] [Abstract][Full Text] [Related]
37. Primary Sjogren's syndrome: current and prospective therapies.
Thanou-Stavraki A; James JA
Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
[TBL] [Abstract][Full Text] [Related]
38. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
[TBL] [Abstract][Full Text] [Related]
40. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
